# Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct04182516/  
OnCo record `nct04182516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is terminated.

## Summary

The registry lists NCT04182516 as terminated, last updated 2024-09-19. Enrolment is 52 actual participants. Interventions: NMS-03305293. Primary measures include Number of Participants with first-cycle dose limiting toxicity. The registry reason for stopping is: The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT04182516
- Phase: 1
- Setting: A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors
- Sponsor: Nerviano Medical Sciences
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT04182516: https://clinicaltrials.gov/study/NCT04182516

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [NMS-03305293](https://onco.cc/drugs/nms-03305293/)

---
JSON: https://onco.cc/api/v1/entities/nct04182516.json